Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 276 participants.

Also called NCT04263038

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 276 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04263038
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Belgium, Canada, France, Netherlands, Switzerland (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT04263038. Randomized; quadruple masking; primary purpose treatment. Start 2020-05-15 (actual); primary completion 2028-05 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism
Acronym
SAFE-SSPE
Condition
Embolism
Condition
Embolism and Thrombosis
Condition
Lung Diseases
Condition
Cardiovascular Diseases
Condition
Respiratory Tract Diseases
Condition
Venous Thromboembolism
Condition
Anticoagulant-induced Bleeding
Condition
Bleeding
Intervention (Drug)
Rivaroxaban
Intervention (Drug)
Placebo
Lead sponsor
Drahomir Aujesky (class: other)
Collaborator
University of Bern (class: other)
Collaborator
Schweizerischer Nationalfonds (class: other)
Collaborator
Leiden University Medical Center (class: other)
Collaborator
The Ottawa Hospital (class: other)
Collaborator
Bayer (class: industry)

Record details

Record id
cardio:ct-nct04263038
Content hash
b00baca0ee19635cd6bac35c136a504f9cf352e1393d371826522105ab9a8846